Shares of Health Care sector company Vertex Pharmaceuticals moved -1.5% today, and are now trading at a price of $404.65. The large-cap stock's daily volume was 1,852,504 compared to its average volume of 1,394,798. The S&P 500 index returned a 1.0% performance.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). The company is based in Boston and has 4,800 full time employees. Its market capitalization is $104,271,429,632.
25 analysts are following Vertex Pharmaceuticals and have set target prices ranging from $325.0 to $500.0 per share. On average, they have given the company a rating of buy. At today's prices, VRTX is trading -1.55% away from its average analyst target price of $411.04 per share.
Over the last year, VRTX's share price has increased by 40.8%, which represents a difference of 17.2% when compared to the S&P 500. The stock's 52 week high is $413.0 per share whereas its 52 week low is $282.21. With average free cash flows of $2.7 Billion that have been growing at an average rate of 25.0% over the last 6 years, Vertex Pharmaceuticals is in a position to continue its strong stock performance trend.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 4,381,100 | 175,900 | 4,205,200 | 7.13 |
| 2022 | 4,129,900 | 204,700 | 3,925,200 | 62.97 |
| 2021 | 2,643,500 | 235,000 | 2,408,500 | -19.55 |
| 2020 | 3,253,500 | 259,800 | 2,993,700 | 100.39 |
| 2019 | 1,569,300 | 75,400 | 1,493,900 | 27.16 |
| 2018 | 1,270,286 | 95,449 | 1,174,837 |
